Introduction .uk
The IASLC Lung Cancer Staging Project: Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvementin the Forthcoming Eighth Edition of the TNM ClassificationFrank C. Detterbeck MD,1 Andrew G. Nicholson MD,2 Wilbur A. Franklin MD,3 Edith M. Marom MD,4 William D. Travis MD,5 Nicolas Girard MD,6 Douglas A. Arenberg MD,7 Vanessa Bolejack MPH,8 Jessica S. Donington MD,9 Peter J. Mazzone MD,10 Lynn T. Tanoue MD,11 Valerie W. Rusch MD,12 John Crowley PhD,8 Hisao Asamura MD13 and Ramon Rami-Porta MD FETCS,14 on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards, Multiple Pulmonary Sites Workgroup and Participating Institutions15 1 Department of Surgery, Yale University, New Haven, CT, United States of America 2 Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, United Kingdom3 Department of Pathology, University of Colorado, Denver, CO, United States of America4 Department of Diagnostic Imaging, Tel-Aviv University, Ramat Gan, Israel 5 Department of Pathology, Sloan-Kettering Cancer Center, New York, NY, United States of America6 Respiratory Medicine Service, H?pital Louis Pradel, Hospices Civils de Lyon, Lyon, France7 Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States of America8 Cancer Research And Biostatistics, Seattle, WA, United States of America9 Department of Thoracic Surgery, New York University, New York, NY, United States of America10 Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, United States of America11 Department of Internal Medicine, Yale University, New Haven, CT, United States of America 12 Thoracic Surgery Service, Sloan-Kettering Cancer Center, New York, NY, United States of America13 Division of Thoracic Surgery, Keio University, School of Medicine, Tokyo, Japan14 Thoracic Surgery Service, Hospital Universitari Mutua Terrassa and CIBERES Lung Cancer Group, Terrassa, Barcelona, Spain15 See AppendixKeywords: Lung cancer, Non-small cell lung cancer, TNM classification, Lung cancer staging, Multiple tumors Abstract: 313 words, Text: 4024 words, 1 Figure, 5 Tables, 22 ReferencesAbstractIntroduction: Patients with lung cancer who harbor multiple pulmonary sites of disease have been challenging to classify; a subcommittee of the IASLC Staging and Prognostic Factors Committee was charged with developing proposals for the 8th edition TNM classification to address this issue.Methods: A systematic literature review and IASLC database analysis was performed to develop proposals for revision in an iterative process involving multispecialty international input and review.Results: Details of the evidence base are summarized in other papers. Four patterns of disease presentation are recognized; the clinical presentation, pathologic correlatesfeatures and biologic behavior of these suggest specific applications of TNM classification rules. First, it is proposed that second primary lung cancers be designated with a T, N and M category for each tumor. Second, tumors with a separate tumor nodule, viewed as intrapulmonary metastatic spread from a single tumor by the pathology community, of the same histologic type (either suspected or proven) should be classified according to the location of the separate nodule relative to the index tumor – T3 for a same-lobe, T4 for a same-side (different lobe), and M1a for an other-side location – with a single N and M category. Third, multiple tumors with prominent ground glass (imaging) or lepidic (histology) features should be designated by the T category of the highest T lesion, the number or “m” in parentheses (#/m) to indicate the multiplicity, and a collective N and M category for all. Finally, diffuse pneumonic-type lung cancers are proposed to be designated by size (or T3) if in one lobe, T4 if involving multiple same-side lobes, and M1a if involving both lungs with a single N and M category for all areas of involvement.Conclusion: We propose to tailor TNM classification of multiple pulmonary sites of lung cancer to reflect unique aspects of 4 different patterns of presentation. We hope this will lead to more consistent classification, clarity in communication, and facilitate further research in the nature and optimal treatment of these entities.IntroductionThe 7th edition of the tumor, node and metastasis (TNM) classification for lung cancer contained some ambiguity with respect to classification of lung cancer with multiple pulmonary sites of involvement. Surveys of experts reveal that there was marked variability in how different people would classify particular tumors, ADDIN EN.CITE <EndNote><Cite><Author>Fonseca</Author><Year>2014</Year><RecNum>7189</RecNum><DisplayText><style face="superscript">1,2</style></DisplayText><record><rec-number>7189</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1426603687">7189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Fonseca, Annabelle</author><author>Detterbeck, Frank C.</author></authors></contributors><titles><title>How many names for a rose: Inconsistent classification of multiple foci of lung cancer due to ambiguous rules</title><secondary-title>Lung Cancer</secondary-title></titles><periodical><full-title>Lung Cancer</full-title></periodical><pages>7-11</pages><volume>85</volume><number>1</number><keywords><keyword>Multi foci</keyword><keyword>Stage classification</keyword><keyword>TNM</keyword><keyword>Lung cancer</keyword><keyword>Non-small cell lung cancer</keyword><keyword>Adenocarcinoma</keyword></keywords><dates><year>2014</year><pub-dates><date>7//</date></pub-dates></dates><isbn>0169-5002</isbn><urls><related-urls><url> app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1436190952">7302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Homer, RJ</author></authors></contributors><titles><title>Pathologists' staging of multiple foci of lung cancer</title><secondary-title>Am J Clin Pathol</secondary-title></titles><periodical><full-title>Am J Clin Pathol</full-title></periodical><pages>701-706</pages><volume>143</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>1,2 thus undermining the primary goal of TNM classification which is to provide a nomenclature for tumor extent that creates homogeneous clusters of tumors. Furthermore, the heterogeneity resulting from this variability hampers the ability to interpret research studies. Defining homogeneous groups is particularly significant among patients with multiple pulmonary sites of lung cancer, as several patterns of presentation are associated with multiple lesions. These exhibit marked differences in biologic behavior, including survival and recurrence patterns. The heterogeneity in classification since the 7th edition of TNM classification arises both from a lack of clear distinction between disease entities as well as ambiguity about how to apply stage classification rules to these patients.Second primary lung cancers have long been recognized by the TNM system although little detail was provided regarding how this diagnosis should be established. Separate tumor nodules were classified as M1 until 1993, when they were defined as raising the T category by 1 when in the same lobe as the primary and as T4 if in a different lobe. In 1997 a separate tumor nodule was classified as T4 if in the same lobe and M1 if in a different lobe (ipsi- or contralateral). In 2010 these were reclassified as T3 for a same-lobe separate nodule (and the term “satellite” nodule for such lesions was abandoned), as T4 for an ipsilateral different-lobe nodule and as M1a for a contralateral nodule. Moreover, previous editions of TNM provided little guidance on what constitutes a separate tumor nodule until the 7th edition, in which the language has turned out to be variously interpreted. ADDIN EN.CITE <EndNote><Cite><Author>Fonseca</Author><Year>2014</Year><RecNum>7189</RecNum><DisplayText><style face="superscript">1,2</style></DisplayText><record><rec-number>7189</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1426603687">7189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Fonseca, Annabelle</author><author>Detterbeck, Frank C.</author></authors></contributors><titles><title>How many names for a rose: Inconsistent classification of multiple foci of lung cancer due to ambiguous rules</title><secondary-title>Lung Cancer</secondary-title></titles><periodical><full-title>Lung Cancer</full-title></periodical><pages>7-11</pages><volume>85</volume><number>1</number><keywords><keyword>Multi foci</keyword><keyword>Stage classification</keyword><keyword>TNM</keyword><keyword>Lung cancer</keyword><keyword>Non-small cell lung cancer</keyword><keyword>Adenocarcinoma</keyword></keywords><dates><year>2014</year><pub-dates><date>7//</date></pub-dates></dates><isbn>0169-5002</isbn><urls><related-urls><url> app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1436190952">7302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Homer, RJ</author></authors></contributors><titles><title>Pathologists' staging of multiple foci of lung cancer</title><secondary-title>Am J Clin Pathol</secondary-title></titles><periodical><full-title>Am J Clin Pathol</full-title></periodical><pages>701-706</pages><volume>143</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>1,2 Furthermore, the 7th edition contained only vague mention of ground glass or lepidic lesions, and predated the 2011 definition of adenocarcinoma subtypes.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UcmF2aXM8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UcmF2aXM8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS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ADDIN EN.CITE.DATA 3,4To provide better clarity for the 8th edition of TNM classification, an international subcommittee of experts conducted a comprehensive review of relevant data. This was used to identify distinct patterns of disease and to develop criteria to categorize lung cancer with multiple pulmonary sites of involvement accordingly. Furthermore, the subcommittee formulated clear instruction on how to apply TNM classification rules to each pattern of disease, taking into account the particular issues that each one presents. The full scope of this process is detailed in additional papers.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZXR0ZXJiZWNrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZXR0ZXJiZWNrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh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ADDIN EN.CITE.DATA 5-7 This paper summarizes the recommendations for lung cancer with multiple pulmonary sites of involvement in one document.Four patterns of presentation are associated with multiple pulmonary sites of lung cancer (Figure 1). First, patients can present with second primary lung cancers. The demographic characteristics, outcomes and recurrence patterns for each tumor are similar to that of single “typical” lung cancers according to the stage and histologic type. Second, some patients with a solid primary lung cancer have one or more separate solid tumor nodule(s) of the same histologic type (referred to as intrapulmonary metastasis in the pathology community). The behavior of these tumors is similar to that of a similar solitary tumor; outcomes are slightly inferior and impacted by how they are treated. A third pattern of disease involves patients presenting with multiple lung cancer nodules with prominent ground glass or lepidic (GG/L) features. This group has different demographic characteristics, excellent outcomes, and infrequent recurrences outside the lung parenchyma. A fourth pattern of disease involves a form of lung cancer that is radiologically similar to a pneumonia (so-called pneumonic-type of lung cancer). Extrathoracic and nodal involvement is infrequent, but prognosis is distinctly worse than for patients with multiple GG/L nodules. MethodsTo develop proposals for revision of the classification of lung cancers with multiple pulmonary sites of involvement, an international multidisciplinary subcommittee of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors committee (SPFC) was formed (i.e. the authors of this paper). This group conducted a comprehensive review of the relevant literature. Details of this process and results are provided in a series of review papers;PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZXR0ZXJiZWNrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh
cj48UmVjTnVtPjcyNTA8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2Ny
aXB0Ij41LTc8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj43MjUwPC9y
ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXB6ZnZwd2Flcnh4
dGVleGV3ODVkcGUwNWVkYXZkZmZzMDV0IiB0aW1lc3RhbXA9IjE0Mjg5MzQ3NTIiPjcyNTA8L2tl
eT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVm
LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkRldHRlcmJlY2ssIEY8L2F1dGhv
cj48YXV0aG9yPkFyZW5iZXJnLCBEb3VnbGFzPC9hdXRob3I+PGF1dGhvcj5Bc2FtdXJhLCBILjwv
YXV0aG9yPjxhdXRob3I+RG9uaW5ndG9uLCBKLjwvYXV0aG9yPjxhdXRob3I+RnJhbmtsaW4sIFc8
L2F1dGhvcj48YXV0aG9yPkdpcmFyZCwgTjwvYXV0aG9yPjxhdXRob3I+TWFyb20sIEVkaXRoIE0u
PC9hdXRob3I+PGF1dGhvcj5NYXp6b25lLCBQLjwvYXV0aG9yPjxhdXRob3I+TmljaG9sc29uLCBB
LjwvYXV0aG9yPjxhdXRob3I+UnVzY2gsIFYuPC9hdXRob3I+PGF1dGhvcj5UYW5vdWUsIEw8L2F1
dGhvcj48YXV0aG9yPlRyYXZpcywgVzwvYXV0aG9yPjxhdXRob3I+UmFtaS1wb3J0YSwgUiwgb24g
YmVoYWxmIG9mIHRoZSBJQVNMQyBTdGFnaW5nIGFuZCBQcm9nbm9zdGljIEZhY3RvcnMgQ29tbWl0
dGVlLCBBZGt2aXNvcnkgQm9hcmRzIGFuZCBQYXJ0aWNpcGF0aW5nIEluc3RpdHV0aW9uczwvYXV0
aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5UaGUgSUFTTEMgTHVu
ZyBDYW5jZXIgU3RhZ2luZyBQcm9qZWN0OiBQcm9wb3NhbHMgZm9yIHJldmlzaW9ucyBvZiB0aGUg
Y2xhc3NmaWNhdGlvbiBvZiBhZGRpdGlvbmFsIHR1bW9yIG5vZHVsZXMgaW4gcGF0aWVudHMgd2l0
aCBsdW5nIGNhbmNlciBpbiB0aGUgZm9ydGhjb21pbmcgRWlnaHRoIEVkaXRpb24gb2YgdGhlIFRO
TSBDbGFzc2lmaWNhdGlvbiBmb3IgTHVuZyBDYW5jZXI8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+
SiBUaG9yYWMgT25jb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVs
bC10aXRsZT5KIFRob3JhYyBPbmNvbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHZvbHVtZT5p
biBwcmVzczwvdm9sdW1lPjxkYXRlcz48eWVhcj4yMDE1PC95ZWFyPjwvZGF0ZXM+PHVybHM+PC91
cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkRldHRlcmJlY2s8L0F1dGhvcj48WWVh
cj4yMDE1PC9ZZWFyPjxSZWNOdW0+NzI1NzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+NzI1
NzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjVwemZ2cHdh
ZXJ4eHRlZXhldzg1ZHBlMDVlZGF2ZGZmczA1dCIgdGltZXN0YW1wPSIxNDI5MTkwMjQxIj43MjU3
PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8
L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5EZXR0ZXJiZWNrLCBGPC9h
dXRob3I+PGF1dGhvcj5BcmVuYmVyZywgRG91Z2xhczwvYXV0aG9yPjxhdXRob3I+QXNhbXVyYSwg
SC48L2F1dGhvcj48YXV0aG9yPkRvbmluZ3RvbiwgSjwvYXV0aG9yPjxhdXRob3I+RnJhbmtsaW4s
IFc8L2F1dGhvcj48YXV0aG9yPkdpcmFyZCwgTjwvYXV0aG9yPjxhdXRob3I+TWFyb20sIEVNPC9h
dXRob3I+PGF1dGhvcj5NYXp6b25lLCBQLjwvYXV0aG9yPjxhdXRob3I+TmljaG9sc29uLCBBLjwv
YXV0aG9yPjxhdXRob3I+UnVzY2gsIFYuPC9hdXRob3I+PGF1dGhvcj5UYW5vdWUsIEw8L2F1dGhv
cj48YXV0aG9yPlRyYXZpcywgVzwvYXV0aG9yPjxhdXRob3I+UmFtaS1Qb3J0YSwgUiBvbiBiZWhh
bGYgb2YgdGhlIElBU0xDIFN0YWdpbmcgYW5kIFByb2dub3N0aWMgRmFjdG9ycyBDb21taXR0ZWUs
IEFkdmlzb3J5IEJvYXJkcy48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxl
cz48dGl0bGU+VGhlIElBU0xDIEx1bmcgQ2FuY2VyIFN0YWdpbmcgUHJvamVjdDogQ3JpdGVyaWEg
dG8gZGlzdGluZ3Vpc2ggc2VwYXJhdGUgcHJpbWFyeSBsdW5nIGNhbmNlcnMgZnJvbSBtZXRhc3Rh
dGljIGZvY2kgaW4gcGF0aWVudHMgd2l0aCB0d28gbHVuZyB0dW1vcnM8L3RpdGxlPjxzZWNvbmRh
cnktdGl0bGU+SiBUaG9yYWMgT25jb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9k
aWNhbD48ZnVsbC10aXRsZT5KIFRob3JhYyBPbmNvbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+
PHZvbHVtZT5pbiBwcm9jZXNzPC92b2x1bWU+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PC9kYXRl
cz48dXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+RGV0dGVyYmVjazwv
QXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJlY051bT43MjU4PC9SZWNOdW0+PHJlY29yZD48cmVj
LW51bWJlcj43MjU4PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p
ZD0iNXB6ZnZwd2Flcnh4dGVleGV3ODVkcGUwNWVkYXZkZmZzMDV0IiB0aW1lc3RhbXA9IjE0Mjkx
OTAzMzUiPjcyNTg8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB
cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkRldHRl
cmJlY2ssIEY8L2F1dGhvcj48YXV0aG9yPkFyZW5iZXJnLCBEb3VnbGFzPC9hdXRob3I+PGF1dGhv
cj5Bc2FtdXJhLCBILjwvYXV0aG9yPjxhdXRob3I+RG9uaW5ndG9uLCBKPC9hdXRob3I+PGF1dGhv
cj5GcmFua2xpbiwgVzwvYXV0aG9yPjxhdXRob3I+R2lyYXJkLCBOPC9hdXRob3I+PGF1dGhvcj5N
YXJvbSwgRU08L2F1dGhvcj48YXV0aG9yPk1henpvbmUsIFAuPC9hdXRob3I+PGF1dGhvcj5OaWNo
b2xzb24sIEEuPC9hdXRob3I+PGF1dGhvcj5SdXNjaCwgVi48L2F1dGhvcj48YXV0aG9yPlRhbm91
ZSwgTDwvYXV0aG9yPjxhdXRob3I+VHJhdmlzLCBXPC9hdXRob3I+PGF1dGhvcj5SYW1pLVBvcnRh
LCBSIG9uIGJlaGFsZiBvZiB0aGUgSUFTTEMgU3RhZ2luZyBhbmQgUHJvZ25vc3RpYyBGYWN0b3Jz
IENvbW1pdHRlZSwgQWR2aXNvcnkgQm9hcmRzLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1
dG9ycz48dGl0bGVzPjx0aXRsZT5UaGUgSUFTTEMgTHVuZyBDYW5jZXIgU3RhZ2luZyBQcm9qZWN0
OiBNdWx0aWZvY2FsIGx1bmcgY2FuY2VyIHByZXNlbnRpbmcgYXMgbXVsdGlwbGUgbm9kdWxlcyB3
aXRoIGdyb3VuZCBnbGFzcyBmZWF0dXJlcy48L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBUaG9y
YWMgT25jb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs
ZT5KIFRob3JhYyBPbmNvbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHZvbHVtZT5pbiBwcm9j
ZXNzPC92b2x1bWU+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PC9kYXRlcz48dXJscz48L3VybHM+
PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZXR0ZXJiZWNrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh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ADDIN EN.CITE.DATA 5-7 a summary of this data is provided in the next section of this paper. In addition, the IASLC database from 1999-2010 was analyzed regarding separate tumor nodules (this was the only pattern of disease for which there was sufficient data in the database). This evidence was then used in an iterative process to develop recommendations. These documents were critically evaluated by an extended workgroup (appendix) in addition to review and eventual endorsement by the entire SPFCBrief Summary of Evidence ReviewSecond Primary Lung CancersA different histologic type is generally sufficient to establish 2 malignant pulmonary lesions as separate primary cancers, provided adequate tissue is available. Similarly, different appearance by a detailed histologic assessment (proportion of subtypes, grade, cytologic and stromal features, etc.) of resected specimens can establish tumors as second primary cancers. However the same (or predominant) histologic type does not by itself clearly establish that the lesions are manifestations of the same tumor. Historical studies, clonality studies and outcomes studies indicate that the large majority of second cancers of the same histologic type are likely to be second primary lung cancers. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7257</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>7257</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190241">7257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>6 Similarly, the same morphologic appearance by a more detailed histologic assessment as noted above should not be taken by itself as clear evidence that two lesions are manifestations of the same tumor; it is only suggestive that two lesions may be related. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7257</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>7257</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190241">7257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>6Assessment of biomarkers (driver gene mutations) is only suggestive, as there is a substantial rate of discordance among different samples of the same tumor and concordance among clearly separate tumors. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7257</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>7257</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190241">7257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>6 Thus, mutational profiling should not be considered definitive and must be considered together with other information. More detailed genetic assessments (comparative genomic hybridization, Next-Gen sequencing) are promising but not sufficiently studied or standardized, and are complex to use in routine clinical practice. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7257</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>7257</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190241">7257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>6Separate Tumor Nodules (Intrapulmonary Metastasis)The IASLC database for the 7th (1990-1999) and 8th edition (1999-2010) included a small proportion of patients who were recorded as having a separate malignant nodule (2.5% and 3.5%, respectively). ADDIN EN.CITE <EndNote><Cite><Author>Goldstraw</Author><Year>2007</Year><RecNum>4597</RecNum><DisplayText><style face="superscript">8,9</style></DisplayText><record><rec-number>4597</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="0">4597</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Goldstraw, Peter</author><author>Crowley, John</author><author>Chansky, Kari</author><author>Giroux, Dorothy J.</author><author>Groome, Patti A.</author><author>Rami-Porta, R</author><author>Postmus, PE</author><author>Rusch, Valerie W.</author><author>Sobin, Leslie</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><pages>706-714</pages><volume>2</volume><number>8</number><dates><year>2007</year></dates><urls></urls></record></Cite><Cite><Author>Goldstraw</Author><Year>2015</Year><RecNum>7304</RecNum><record><rec-number>7304</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1436293747">7304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Goldstraw, P et al</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: proposals for the revision of the stage grouping in the forthcoming (8th) edition of the TNM classification of lung cancer</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in preparation</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>8,9 It appears that these patients primarily fit a pattern of disease consisting of a typical primary lung cancer (i.e. a solid mass) with a separate solid tumor nodule of the same histologic type (rarely more than one). The outcomes of these patients in the IASLC database analysis was consistent with those gathered in a systematic literature review. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7250</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>7250</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1428934752">7250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J.</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, Edith M.</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-porta, R, on behalf of the IASLC Staging and Prognostic Factors Committee, Adkvisory Boards and Participating Institutions</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Proposals for revisions of the classfication of additional tumor nodules in patients with lung cancer in the forthcoming Eighth Edition of the TNM Classification for Lung Cancer</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in press</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>5 Among clinically staged patients, overall survival (OS) decreased progressively by location of the separate tumor nodule relative to the primary tumor (same lobe > same lung [different lobe] > other lung), ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7250</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>7250</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1428934752">7250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J.</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, Edith M.</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-porta, R, on behalf of the IASLC Staging and Prognostic Factors Committee, Adkvisory Boards and Participating Institutions</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Proposals for revisions of the classfication of additional tumor nodules in patients with lung cancer in the forthcoming Eighth Edition of the TNM Classification for Lung Cancer</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in press</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>5 consistent with the analysis for the 7th edition. However, OS seems to have been primarily impacted by the treatment given; there was no difference in OS by separate tumor nodule location among only surgically managed patients or among non-surgically managed patients. Other confounding factors include varying proportions of incidentally discovered nodules (not identified preoperatively) and selection factors leading some patients to be managed surgically and others non-surgically. Because of an inability to separate the influence of these various factors, the TNM classification of the 7th edition for separate tumor nodules was maintained. Multifocal Lung Adenocarcinoma with Ground Glass/Lepidic Features)An increasing number of lung cancer patients are encountered that have multiple sub-solid nodules (either pure ground glass or part-solid) on CT examination. The pathologic correlates of this appearance are lepidic predominant adenocarcinoma (LPA), minimally invasive adenocarcinoma (MIA), or adenocarcinoma in situ (AIS) with or without other subtypes of adenocarcinoma as lesser components.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UcmF2aXM8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UcmF2aXM8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS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ADDIN EN.CITE.DATA 3 The ground glass versus solid component seen by CT generally corresponds to lepidic versus invasive growth. The nature of these lesions and their relationship to one another are not yet fully understood; they are viewed as separate tumors with an in situ or invasive component that has arisen from a predominant non-invasive component. Clonality studies comparing multiple such tumors in the same patient are conflicting. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7258</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>7258</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190335">7258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Multifocal lung cancer presenting as multiple nodules with ground glass features.</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>7The patients with such lung adenocarcinomas that present as multiple nodules with ground glass features have a decreased propensity for nodal or systemic spread and an increased propensity to develop additional sub-solid cancers. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7258</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>7258</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190335">7258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Multifocal lung cancer presenting as multiple nodules with ground glass features.</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>7 Furthermore, they often exhibit a more indolent behavior. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7258</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>7258</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190335">7258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Multifocal lung cancer presenting as multiple nodules with ground glass features.</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>7 There are often numerous additional GG/L foci, and the patients are often women and non-smokers. These lesions are easy to recognize clinically (by CT imaging) and pathologically (prominent lepidic component). Thus this pattern of disease has many distinct features.Pneumonic-Type of Lung AdenocarcinomaA subset of patients exhibits a diffuse consolidative pattern (“pneumonic-type” of lung adenocarcinoma).PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XaXNsZXo8L0F1dGhvcj48WWVhcj4yMDAzPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XaXNsZXo8L0F1dGhvcj48WWVhcj4yMDAzPC9ZZWFyPjxS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ADDIN EN.CITE.DATA 10-12 There are typically areas of ground glass as well as solid consolidation. This pattern of clinical presentation typically correlates with invasive mucinous adenocarcinoma, ADDIN EN.CITE <EndNote><Cite><Author>WHO</Author><Year>2015</Year><RecNum>7254</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>7254</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1428952329">7254</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>WHO</author></authors><secondary-authors><author>Bosman, FT</author><author>Jaffe, ES</author><author>Lakhani, SR</author><author>Ohgaki, H</author></secondary-authors><tertiary-authors><author>Travis, WD</author><author>Brambilla, E.</author><author>Burke, AP</author><author>Marx, Alexander</author><author>Nicholson, AG</author></tertiary-authors></contributors><titles><title>WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart</title><secondary-title>World Health Organization Classification of Tumours</secondary-title></titles><pages>411</pages><edition>4th Edition</edition><dates><year>2015</year></dates><pub-location>Lyon, France</pub-location><publisher>International Agency for Research on Cancer (IARC)</publisher><urls></urls></record></Cite></EndNote>4 which characteristically show a goblet and/or columnar cell morphology with abundant intracytoplasmic mucin. Although invasive mucinous adenocarcinoma often shows lepidic predominant growth, extensive sampling usually reveals invasive foci, sometimes with desmoplastic stroma. Invasive mucinous adenocarcinoma may show a heterogeneous mixture of adenocarcinoma subtypes. Surrounding alveolar spaces often fill with mucin. This heterogeneous histologic appearance is frequently similar throughout areas of involvement in a particular patient. A detailed study of a patient with diffuse pneumonic adenocarcinoma suggested different clonality in each of the 5 lobes examined; ADDIN EN.CITE <EndNote><Cite><Author>Nanki</Author><Year>2002</Year><RecNum>7161</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>7161</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1424186726">7161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Nanki, N</author><author>Fujita, J</author><author>Hojo, S</author><author>Yang, Yue</author><author>Bandoh, S</author><author>Ohara, N</author><author>Miyatani, K</author><author>Yamaji, Y</author><author>Ohtsuki, Y</author><author>Ishida, T.</author></authors></contributors><titles><title>Evaluation of the clonality of multilobar bronchioloalveolar carcinoma of the lung</title><secondary-title>Am J Clin Oncol</secondary-title></titles><periodical><full-title>Am J Clin Oncol</full-title></periodical><pages>291-295</pages><volume>25</volume><number>3</number><dates><year>2002</year></dates><urls></urls></record></Cite></EndNote>13 it is controversial how to interpret this case. The majority of these patients have an invasive mucinous adenocarcinoma, the rest are mixed or non-mucinous adenocarcinomas. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7258</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>7258</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190335">7258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Multifocal lung cancer presenting as multiple nodules with ground glass features.</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>7 These patients typically present without nodal or systemic metastases despite diffuse pulmonary involvement; the occasional use of double lung transplantation as a treatment underscores this.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CYXJsZXNpPC9BdXRob3I+PFllYXI+MjAwMzwvWWVhcj48
UmVjTnVtPjM5NDg8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0
Ij4xNC0xNjwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjM5NDg8L3Jl
Yy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSI1cHpmdnB3YWVyeHh0
ZWV4ZXc4NWRwZTA1ZWRhdmRmZnMwNXQiIHRpbWVzdGFtcD0iMCI+Mzk0ODwva2V5PjwvZm9yZWln
bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29u
dHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QmFybGVzaSwgRi48L2F1dGhvcj48YXV0aG9yPkRv
ZGRvbGksIEMuPC9hdXRob3I+PGF1dGhvcj5HaW1lbmV6LCBDLjwvYXV0aG9yPjxhdXRob3I+Q2hl
dGFpbGxlLCBCLjwvYXV0aG9yPjxhdXRob3I+R2l1ZGljZWxsaSwgUi48L2F1dGhvcj48YXV0aG9y
PkZ1ZW50ZXMsIFAuPC9hdXRob3I+PGF1dGhvcj5LbGVpc2JhdWVyLCBKLiBQLjwvYXV0aG9yPjxh
dXRob3I+VGhvbWFzLCBQLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1h
ZGRyZXNzPkRlcGFydG1lbnQgb2YgVGhvcmFjaWMgT25jb2xvZ3ksIEZhY3VsdHkgb2YgTWVkaWNp
bmUsIFVuaXYuIE1lZGl0ZXJyYW5lZSAoQWl4LU1hcnNlaWxsZSBJSSksIE1hcnNlaWxsZSwgRnJh
bmNlLiBmYWJyaWNlLmJhcmxlc2lAbWFpbC5hcC1obS5mcjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+
PHRpdGxlPkJyb25jaGlvbG9hbHZlb2xhciBjYXJjaW5vbWE6IG15dGhzIGFuZCByZWFsaXRpZXMg
aW4gdGhlIHN1cmdpY2FsIG1hbmFnZW1lbnQ8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+RXVyIEog
Q2FyZGlvdGhvcmFjIFN1cmc8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48
ZnVsbC10aXRsZT5FdXIgSiBDYXJkaW90aG9yYWMgU3VyZzwvZnVsbC10aXRsZT48L3BlcmlvZGlj
YWw+PHBhZ2VzPjE1OS02NDwvcGFnZXM+PHZvbHVtZT4yNDwvdm9sdW1lPjxudW1iZXI+MTwvbnVt
YmVyPjxkYXRlcz48eWVhcj4yMDAzPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRlPjwv
cHViLWRhdGVzPjwvZGF0ZXM+PGFjY2Vzc2lvbi1udW0+MTI4NTMwNjI8L2FjY2Vzc2lvbi1udW0+
PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9lbnRy
ZXovcXVlcnkuZmNnaT9jbWQ9UmV0cmlldmUmYW1wO2RiPVB1Yk1lZCZhbXA7ZG9wdD1DaXRhdGlv
biZhbXA7bGlzdF91aWRzPTEyODUzMDYyPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVj
b3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPmRlIFBlcnJvdDwvQXV0aG9yPjxZZWFyPjIwMDQ8L1ll
YXI+PFJlY051bT4zNzE5PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4zNzE5PC9yZWMtbnVt
YmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXB6ZnZwd2Flcnh4dGVleGV3
ODVkcGUwNWVkYXZkZmZzMDV0IiB0aW1lc3RhbXA9IjAiPjM3MTk8L2tleT48L2ZvcmVpZ24ta2V5
cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1
dG9ycz48YXV0aG9ycz48YXV0aG9yPmRlIFBlcnJvdCwgTS48L2F1dGhvcj48YXV0aG9yPkNoZXJu
ZW5rbywgUy48L2F1dGhvcj48YXV0aG9yPldhZGRlbGwsIFQuIEsuPC9hdXRob3I+PGF1dGhvcj5T
aGFyZ2FsbCwgWS48L2F1dGhvcj48YXV0aG9yPlBpZXJyZSwgQS4gRi48L2F1dGhvcj48YXV0aG9y
Pkh1dGNoZW9uLCBNLjwvYXV0aG9yPjxhdXRob3I+S2VzaGF2amVlLCBTLjwvYXV0aG9yPjwvYXV0
aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPlRvcm9udG8gTHVuZyBUcmFuc3BsYW50
IFByb2dyYW0sIFVuaXZlcnNpdHkgb2YgVG9yb250bywgQ2FuYWRhLjwvYXV0aC1hZGRyZXNzPjx0
aXRsZXM+PHRpdGxlPlJvbGUgb2YgbHVuZyB0cmFuc3BsYW50YXRpb24gaW4gdGhlIHRyZWF0bWVu
dCBvZiBicm9uY2hvZ2VuaWMgY2FyY2lub21hcyBmb3IgcGF0aWVudHMgd2l0aCBlbmQtc3RhZ2Ug
cHVsbW9uYXJ5IGRpc2Vhc2U8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBDbGluIE9uY29sPC9z
ZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBDbGluIE9u
Y29sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NDM1MS02PC9wYWdlcz48dm9sdW1l
PjIyPC92b2x1bWU+PG51bWJlcj4yMTwvbnVtYmVyPjxkYXRlcz48eWVhcj4yMDA0PC95ZWFyPjxw
dWItZGF0ZXM+PGRhdGU+RGVjIDE8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48YWNjZXNzaW9u
LW51bT4xNTUxNDM3NjwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0
cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L2VudHJlei9xdWVyeS5mY2dpP2NtZD1SZXRyaWV2ZSZh
bXA7ZGI9UHViTWVkJmFtcDtkb3B0PUNpdGF0aW9uJmFtcDtsaXN0X3VpZHM9MTU1MTQzNzY8L3Vy
bD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+QWht
YWQ8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxSZWNOdW0+NzE5NTwvUmVjTnVtPjxyZWNvcmQ+
PHJlYy1udW1iZXI+NzE5NTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIg
ZGItaWQ9IjVwemZ2cHdhZXJ4eHRlZXhldzg1ZHBlMDVlZGF2ZGZmczA1dCIgdGltZXN0YW1wPSIx
NDI3MTM4MzEzIj43MTk1PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu
YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5B
aG1hZCwgVXNtYW48L2F1dGhvcj48YXV0aG9yPldhbmcsIFp1b2hlbmc8L2F1dGhvcj48YXV0aG9y
PkJyeWFudCwgQXllc2hhIFMuPC9hdXRob3I+PGF1dGhvcj5LaW0sIEFudGhvbnkgVy48L2F1dGhv
cj48YXV0aG9yPkt1a3JlamEsIEphc2xlZW48L2F1dGhvcj48YXV0aG9yPk1hc29uLCBEYXZpZCBQ
LjwvYXV0aG9yPjxhdXRob3I+QmVybXVkZXosIENocmlzdGlhbiBBLjwvYXV0aG9yPjxhdXRob3I+
RGV0dGVyYmVjaywgRnJhbmsgQy48L2F1dGhvcj48YXV0aG9yPkJvZmZhLCBEYW5pZWwgSi48L2F1
dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+T3V0Y29tZXMgZm9y
IEx1bmcgVHJhbnNwbGFudGF0aW9uIGZvciBMdW5nIENhbmNlciBpbiB0aGUgVW5pdGVkIE5ldHdv
cmsgZm9yIE9yZ2FuIFNoYXJpbmcgUmVnaXN0cnk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW5u
IFRob3JhYyBTdXJnPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt
dGl0bGU+QW5uIFRob3JhYyBTdXJnPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+OTM1
LTk0MTwvcGFnZXM+PHZvbHVtZT45NDwvdm9sdW1lPjxudW1iZXI+MzwvbnVtYmVyPjxkYXRlcz48
eWVhcj4yMDEyPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+OS8vPC9kYXRlPjwvcHViLWRhdGVzPjwv
ZGF0ZXM+PGlzYm4+MDAwMy00OTc1PC9pc2JuPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw
Oi8vd3d3LnNjaWVuY2VkaXJlY3QuY29tL3NjaWVuY2UvYXJ0aWNsZS9waWkvUzAwMDM0OTc1MTIw
MDk0MTE8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVt
Pmh0dHA6Ly9keC5kb2kub3JnLzEwLjEwMTYvai5hdGhvcmFjc3VyLjIwMTIuMDQuMDY5PC9lbGVj
dHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CYXJsZXNpPC9BdXRob3I+PFllYXI+MjAwMzwvWWVhcj48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=
ADDIN EN.CITE.DATA 14-16 Although the rate of progression is often slow, survival is markedly worse than for patients with GG/L tumors. Thus, although there are some similarities between the multiple GG/L pattern of disease and the pneumonic pattern of disease (e.g. ground glass and lepidic components, decreased propensity for nodal and systemic involvement), there are sufficient differences to consider this a distinct pattern of disease.Second Primary Lung CancersDescriptionCriteria to identify 2 tumor foci as either separate primary tumors or related (i.e. arising from a single source) are summarized in Table 1. Some criteria are generally definitive by themselves, while others are suggestive but must be considered together with all available information. The relative weight to give to a particular suggestive observation will depend on several factors such as the degree of similarity or difference, the reliability of the assessment, and what data is available (e.g. the extent of prior imaging available, tissue may consist of a limited biopsy or resection specimens). It is easier to define criteria that identify 2 malignancies as separate than criteria that conclusively establish that the tumors are identical. Ideally, a decision to classify 2 (or more) lesions as synchronous primary cancers or 2 identical foci of a single cancer should be based on the judgment of an experienced multidisciplinary team, taking into account all factors (e.g. clinical, imaging, histological etc.).Proposed TNM ClassificationTwo (or more) synchronous primary lung cancers should be classified separately, each with a T, N, and M descriptor, i.e. a T, N, and M for one tumor and another T, N and M for the other tumor. For example, a patient with a 2.2 cm squamous cell cancer in the right upper lobe, a 3.5 cm adenocarcinoma in the left upper lobe with adenocarcinoma in a L11 node by endobronchial ultrasound aspiration, and no other evidence of nodal or systemic metastases should be classified as having a T1c N0 M0 squamous cell cancer and a T2a N1 M0 adenocarcinoma.This TNM classification of tumors judged to be 2nd primary lung cancers should be applied to both synchronous or metachronous 2nd primary lung cancers, and whether the 2 primary tumors are in different lungs, different lobes or in the same lobe. Furthermore, this classification should be applied to synchronous primary lung cancers recognized clinically or grossly as well as those only recognized on pathologic examination. Separate Tumor Nodule (Intrapulmonary Metastasis)DescriptionPatients should be classified as having separate tumor nodule(s) when there is a “classic” lung cancer (i.e. solid, spiculated) and one (or more) solid separate lung nodules, either presumed (clinical staging) or proven (pathologic staging after comprehensive histologic assessment) to be metastatic from the primary lung cancer; criteria are summarized in Table 2. Typically there is one additional nodule, although there may be more than one.However, the designation of separate tumor nodule(s) should not be used if it is judged that the patient has synchronous primary lung cancers (as defined in the previous section). Furthermore, the designation of separate tumor nodule(s) should not be used in patients with multifocal GG/L lung adenocarcinoma (multiple nodules with ground glass features or multiple foci of LPA, MIA, AIS – see next section). Proposed TNM ClassificationThe TNM classification of a separate tumor nodule(s) (intapulmonary metastasisof the same histologic type) is assigned based on the location of the nodule relative to the primary tumor site. If it is in the same lobe, the tumor is designated as T3, in the same lung (different lobe) as T4, and if in the contralateral lung as M1a. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7250</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>7250</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1428934752">7250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J.</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, Edith M.</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-porta, R, on behalf of the IASLC Staging and Prognostic Factors Committee, Adkvisory Boards and Participating Institutions</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Proposals for revisions of the classfication of additional tumor nodules in patients with lung cancer in the forthcoming Eighth Edition of the TNM Classification for Lung Cancer</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in press</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>5 This applies regardless of whether there is involvement of nodal sites or distant (extrathoracic) sites. In other words, such separate tumor nodules in the lung determine the T category even when there are many sites of extrathoracic metastases (but the tumor would be classified as M1b or M1c because of the extrathoracic metastases). Finally, this classification should be applied to separate tumor nodules recognized clinically or grossly as well as those only recognized on pathologic examination.Multifocal Lung Adenocarcinoma with Ground Glass/Lepidic Features)DescriptionPatients with this pattern of disease present with multiple sub-solid tumor nodules (either pure GGN or part-solid). A GGN is a focal nodular area of increased lung attenuation on CT, including both well and poorly defined lesions, through which normal parenchymal structures, including airways and vessels, can be visualized. ADDIN EN.CITE <EndNote><Cite><Author>Naidich</Author><Year>2013</Year><RecNum>5808</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>5808</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1374777411">5808</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Naidich, David P.</author><author>Bankier, Alexander A.</author><author>MacMahon, Heber</author><author>Schaefer-Prokop, Cornelia M.</author><author>Pistolesi, Massimo</author><author>Goo, Jin Mo</author><author>Macchiarini, Paolo</author><author>Crapo, James D.</author><author>Herold, Christian J.</author><author>Austin, John H.</author><author>Travis, William D.</author></authors></contributors><titles><title>Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society</title><secondary-title>Radiology</secondary-title></titles><periodical><full-title>Radiology</full-title></periodical><pages>304-317</pages><volume>266</volume><number>1</number><dates><year>2013</year></dates><urls><related-urls><url> A sub-solid nodule can be either purely ground glass or a part-solid nodule (usually still >50% ground glass but with a solid component). Tumors should be categorized as multifocal lung adenocarcinoma if there is a malignant sub-solid nodule (either suspected or proven) and other nodules with ground glass features, regardless of whether the other lesions are biopsied or not, and if biopsied, regardless of whether they are shown to be LPA, MIA or AIS (Table 3). ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7258</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>7258</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1429190335">7258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, EM</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-Porta, R on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards.</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Multifocal lung cancer presenting as multiple nodules with ground glass features.</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>7 Frequently multifocal lung adenocarcinoma patients have 3-10 (or more) nodules. This categorization should also apply to patients in which a subsolid lesion appears to have arisen from a GGN (or a lepidic background), but in which the lesions haves become >50% solid (or invasive), provided that other nodules with ground glass features are present as well. Multifocal lung cancer is essentially only seen as a manifestation of adenocarcinoma. The pathologic designation of multifocal lung cancer should be used when there are multiple resected lesions that are either LPA, MIA or AIS with or without other subtypes of adenocarcinoma as lesser components. It is appropriate to combine pathologic identification of one focus of LPA, MIA or AIS with clinical information that there are other, non-resected sub-solid nodules (e.g. in other lobes). The GG/L category should be used whether a detailed histologic assessment (i.e. proportion of subtypes, etc.) shows the lesions to have a matching appearance or to be different. The multifocal GG/L lung adenocarcinoma designation should not be applied to patients with multiple GGNs which are thought to all represent benign or preneoplastic lesions (i.e. AAH). Pure GGNs ≤5 mm and foci of AAH should not be counted, although such lesions are often present in patients with multifocal GG/L adenocarcinoma.Proposed TNM ClassificationMultifocal GG/L adenocarcinoma should be classified by the T category of the lesion with the highest T with the number of lesions (#) or simply (m) for multiple indicated in parentheses, and an N and M category that applies to all of the multiple tumor foci collectively – e.g. T1a(4) N0 M0. The apparent decreased propensity for nodal and distant metastases and increased propensity to additional lung lesions supports the concept of a single N and M for all of the pulmonary lesions. The lesion size is determined by the largest diameter of the solid component (by CT) or the invasive component under the microscope; a designation of Tis should be used for AIS and T1a(mi) for MIA. ADDIN EN.CITE <EndNote><Cite><Author>Travis</Author><Year>2015</Year><RecNum>7308</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>7308</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1436988685">7308</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Travis, D</author><author>Asamura, H.</author><author>Bankier, A. A.</author><author>Detterbeck, F</author><author>Goo, JM</author><author>MacMahon, H.</author><author>Naidich, D. P.</author><author>Nicholson, A.</author><author>Powell, CA</author><author>Prokop, M.</author><author>Rami-Porta, Ramon</author><author>Rusch, V.</author><author>van Schil, P</author><author>Yatabe, Y on behalf of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and Advisory Board Members</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Proposals for coding T categories for adenocarcinoma in situ and minimally invasive adenocarcinoma, and for measurement of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM Classification of Lung Cancer</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in process</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>18The T(#/m) multifocal classification should be applied equally whether the lesions are in the same lobe, or different ipsilateral or contralateral lobes. Furthermore, the T(#/m) multifocal classification should be applied to both grossly recognizable lesions as well as those that are only discovered on pathological examination (microscopically or otherwise).Diffuse Pneumonic-Type of Lung AdenocarcinomaDescriptionThe category of a pneumonic-type of lung adenocarcinoma refers to tumors with a consolidative pattern by CT, either confined to a particular area (segment or lobe) or diffusely in the lung parenchyma (Table 4). The parenchymal borders of the tumor are infiltrative and typically not well demarcated. The tumor may be confined to one region (e.g. segment, lobe) or involve several regions (either confluent or separated) or diffusely involve both lungs. The involved areas typically are a mixture of ground glass and dense consolidation with frequent air bronchograms radiologically and lepidic and invasive foci microscopically. The majority of pneumonic-type of lung cancers are invasive mucinous adenocarcinomas, the rest are either non-mucinous or mixed mucinous and nonmucinous tumors.Proposed TNM ClassificationIn the case of a pneumonic-type of adenocarcinoma with a single area of tumor, it is straightforward to apply the TNM classification as described for lung cancer in general (e.g. the T category determined by size, N and M determined by nodal or extrathoracic involvement). ADDIN EN.CITE <EndNote><Cite><Author>Rami-Porta</Author><Year>2015</Year><RecNum>7246</RecNum><DisplayText><style face="superscript">9,19</style></DisplayText><record><rec-number>7246</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1428497609">7246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Rami-Porta, R</author><author>Bolejack, Vanessa</author><author>Crowley, J</author><author>Ball, David</author><author>Kim, J.</author><author>Lyons, Gustavo</author><author>Rice, T. W.</author><author>Suzuki, K</author><author>Thomas, CF</author><author>Travis, WD</author><author>Yi-Long, W on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and participating Institutions</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM Classification for Lung Cancer </title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><pages>990-1003</pages><volume>10</volume><number>7</number><dates><year>2015</year></dates><urls></urls></record></Cite><Cite><Author>Goldstraw</Author><Year>2015</Year><RecNum>7304</RecNum><record><rec-number>7304</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1436293747">7304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Goldstraw, P et al</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: proposals for the revision of the stage grouping in the forthcoming (8th) edition of the TNM classification of lung cancer</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in preparation</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>9,19 In the case of multiple pulmonary sites of involvement, the T or M category should be determined by the location of the areas of involvement: T3 if confined to one lobe, T4 if involving different lobes in one lung, and M1a if involving both lungs. If the tumor involves both lungs, the T category should be designated according to the appropriate T category for the side with the greatest amount of tumor (i.e size or T3 if in one lobe, T4 if in more than 1 lobe on that side). Because size may be difficult to determine, when the area of involvement extends into an adjacent lobe (as well as a discrete separate area of involvement in an adjacent lobe) the T4 designation should be applied (recognizing extension into another lobe). If the involvement is confined to a single lobe but hard to measure, a designation of T3 should be used. The appropriate N category is chosen that applies to all pulmonary sites of the primary tumor collectively; pleural/pericardial tumor nodules or distant metastases will lead to an M1a, M1b or M1c designation. The classification should be applied to both grossly recognizable lesions as well as those that are only discovered on histologic examination. A detailed histologic assessment to determine whether multiple details are exactly matching or not is not required for pneumonic-type of lung cancer.We propose that the schema for application of TNM classification described for pneumonic-type adenocarcinoma also be used for miliary forms of adenocarcinoma. Because size of miliary involvement is inherently difficult to determine, miliary involvement in a single lobe should be classified as T3 without regard to size.DiscussionThis paper summarizes proposals for the 8th edition of the TNM classification of malignant tumors for patients with lung cancer who present with multiple pulmonary sites of involvement (Table 5). Classification of these tumors can be challenging; the goal was to provide definitions with sufficient clarity to lead to consistent classification. The development of these proposals was conducted by a specific subcommittee of the IASLC SPFC according to a formal process involving a systematic review of the relevant literature, and an analysis of the IASLC database.Although a brief summary of background evidence is provided, full details are beyond the scope of this paper. A systematic review of the literature regarding the definition of 2nd primary lung cancer, outcomes for separate tumor nodules (intrapulmonary metastases), multifocal GG/L lung adenocarcinoma and pneumonic-type of adenocarcinoma as well as an analysis of the IASLC database are provided in other papers.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZXR0ZXJiZWNrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZXR0ZXJiZWNrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh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ADDIN EN.CITE.DATA 5-7 This evidence informed the proposed criteria for patterns of disease that manifest multiple pulmonary sites of lung cancer and the application of the stage classification system described in this paper.A system of nomenclature to classify anatomic tumor extent cannot be equated as a treatment guideline. Nomenclature can facilitate the discussion of how to treat patients, but patient management is defined by studies specifically focused on particular patients, particular treatments and the efficacy thereof. Furthermore, the impact of attitudes towards treatment and the prevalence of particular treatment approaches should not be confused with a prognostic impact that is inherent to a tumor characteristic. For example, separate contralateral tumor nodule(s) (intrapulmonary metastases) have been reported to have a poor prognosis. However, almost all of these patients have been managed non-operatively (i.e. palliatively), although good outcomes are reported after resection (in limited data). Hence the general prognosis may be more reflective of the attitude towards treatment than an inherent prognostic implication of such nodules per se. ADDIN EN.CITE <EndNote><Cite><Author>Detterbeck</Author><Year>2015</Year><RecNum>7250</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>7250</rec-number><foreign-keys><key app="EN" db-id="5pzfvpwaerxxteexew85dpe05edavdffs05t" timestamp="1428934752">7250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Detterbeck, F</author><author>Arenberg, Douglas</author><author>Asamura, H.</author><author>Donington, J.</author><author>Franklin, W</author><author>Girard, N</author><author>Marom, Edith M.</author><author>Mazzone, P.</author><author>Nicholson, A.</author><author>Rusch, V.</author><author>Tanoue, L</author><author>Travis, W</author><author>Rami-porta, R, on behalf of the IASLC Staging and Prognostic Factors Committee, Adkvisory Boards and Participating Institutions</author></authors></contributors><titles><title>The IASLC Lung Cancer Staging Project: Proposals for revisions of the classfication of additional tumor nodules in patients with lung cancer in the forthcoming Eighth Edition of the TNM Classification for Lung Cancer</title><secondary-title>J Thorac Oncol</secondary-title></titles><periodical><full-title>J Thorac Oncol</full-title></periodical><volume>in press</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>5 Historically, classification of (and management of patients with) multiple pulmonary sites of lung cancer has been based on speculation primarily about how physical translocation of a malignant cell from one site to another might occur. However, there is now extensive data that the process of metastasis is highly complex, influenced not only by tumor-cell-intrinsic genetic and epigenetic determinants but also a complex array of tumor-host-interactions at both the primary and metastatic sites.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYWxhc3R5YW48L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYWxhc3R5YW48L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFy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ADDIN EN.CITE.DATA 6,20-22 Tumor cells transform to mesenchymal cells and back again during the process of metastasis, exist in various states and in permissive niches, and there is a complex bidirectional migration between primary, metastatic and other sites. This is governed by multiple pathways, cell signaling, and microenvironment characteristics.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYWxhc3R5YW48L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYWxhc3R5YW48L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFy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ADDIN EN.CITE.DATA 6,20-22 Thus, speculative rationale based primarily on physical translocation of a tumor cell is refuted by extensive evidence. Terms such as lymphatic and hematogenous spread are based on oversimplified concepts and should not dictate classification or treatment of patients; furthermore they hamper consideration of the true determinants of metastasis.Classification inherently involves drawing a line of separation, and there are always borderline zones where the distinction becomes difficult. Furthermore, there will always be patients with unusual presentations that defy classification. We acknowledge these facts, but hope that the structure provided will allow the large majority of patients to be classified easily and consistently and that the guidance provided makes a “best judgment” classification easier in the particularly difficult cases.ConclusionThis paper describes proposed definitions to classify tumors in patients who present with more than one pulmonary site of lung cancer for the 8th edition of the TNM classification. We distinguish several patterns of disease that exhibit multiple pulmonary sites of lung cancer. These are associated with different biologic behavior; defining homogeneous cohorts of tumors requires both clarity about these categories as well as consistent application of TNM classification rules. Specifically, these patterns of disease involve patients with synchronous primary lung cancers, those with a separate solid tumor nodule(s) (intrapulmonary metastases), multifocal lung cancer presenting as multiple nodules with ground glass/lepidic adenocarcinomafeatures, and diffuse pneumonic-type of adenocarcinoma. Synchronous primary cancers are classified with a T, N and M category for each tumor; separate tumor nodules (intrapulmonary metastases) result in a T3, T4 or M1a category depending on the separate nodule location relative to the primary tumor; multifocal GG/L adenocarcinomas tumors are classified by the highest T lesion, the number or m for multiple in parentheses (#/m) and an N and M category for all tumor nodules collectively; and for pneumonic-type adenocarcinoma the T component is classified by size or as T3 if in one lobe, as T4 if in 2 ipsilateral lobes and M1a if contralateral with a single N and M category for all sites of pulmonary involvement collectively. These proposals are based on a systematic review of relevant literature, extensive deliberations of an international multidisciplinary expert panel, and several additional levels of review. We hope this leads to greater ease and consistency in classification of these tumors, while recognizing that there will always be areas of difficulty and tumors that are challenging to classify. We also recognize that the system will need to be refined as further knowledge is gained. TablesTable 1: Criteria to Distinguish Second Primary vs. Related TumorsClinical Criteria*Tumors may be considered second primary tumors if:They are clearly of a different histologic type (e.g. squamous carcinoma and adenocarcinoma) by biopsyTumors may be considered to be arising from one another if:Exactly matching breakpoints are identified by comparative genomic hybridizationRelative arguments that favor separate tumors:Different radiographic appearance or metabolic uptakeDifferent biomarker pattern (driver gene mutations)Different rates of growth (if previous imaging is available)Absence of nodal or systemic metastasesRelative arguments that favor a single tumor source:The same radiographic appearanceSimilar growth patterns (if previous imaging is available)Significant nodal or systemic metastasesThe same biomarker pattern (and same histotype)*A comprehensive histologic assessment is not included in clinical staging, as it requires that the entire specimen has been resected.Pathologic Criteria (i.e. after resection)Tumors may be considered second primary tumors if:They are clearly of a different histologic type (e.g. squamous carcinoma and adenocarcinoma)They are clearly different by a comprehensive histologic assessmentSquamous carcinomas that have arisen from carcinoma in situTumors may be considered to be arising from one another if:Exactly matching breakpoints are identified by comparative genomic hybridizationRelative arguments that favor separate tumors (to be considered together with clinical factors):Different biomarker patternAbsence of nodal or systemic metastasesRelative arguments that favor a single tumor source (to be considered together with clinical factors):Matching appearance on comprehensive histologic assessmentThe same biomarker patternSignificant nodal or systemic metastasesTable 2: Criteria to Categorize a Lesion as a Separate Tumor Nodule (Intrapulmonary Metastasis)Clinical CriteriaTumors should be considered to have a separate tumor nodule(s) if:There is a solid lung cancer and a separate tumor nodule(s) with a similar solid appearance and with (presumed) matching histology This applies whether or not the lesions have been biopsied, provided there is strong suspicion that the lesions are histologically identical This applies whether or not there are sites of extrathoracic metastases AND provided that:The lesions are NOT judged to be synchronous primary lung cancersThe lesions are NOT Multifocal GG/L Lung Cancer (multiple nodules with ground glass/lepidic features) or pneumonic-type of lung cancerPathologic Criteria Tumors should be considered to have a separate tumor nodule (intrapulmonary metastasis) if:There is a separate tumor nodule(s) of cancer in the lung viewed as coming from a single tumor source after comprehensive histological assessmentwith an identical histologic appearance to a primary lung cancerAND provided that:The lesions are NOT judged to be synchronous primary lung cancersThe lesions are NOT multiple foci of LPA, MIA, AISAIS, adenocarcinoma in situ; GG/L, ground glass/lepidic; LPA, lepidic predominant adenocarcinoma; MIA, minimally invasive adenocarcinomaTable 3: Criteria to Categorize a Tumor as Multifocal GG/L AdenocarcinomaClinical CriteriaTumors should be considered multifocal GG/L lung adenocarcinoma if:There are multiple sub-solid nodules (either pure ground glass or part-solid), with at least one suspected (or proven) to be cancer. This applies whether or not the nodules have been biopsied This applies if the other nodules(s) are suspected to be AIS, MIA or LPA This applies if a nodule has become >50% solid but is judged to have arisen from a GGN, provided there are other sub-solid nodules GGN lesions <5mm or lesions suspected to be AAH are not countedPathologic Correlatesriteria Tumors should be considered multifocal GG/L lung adenocarcinoma if:There are multiple foci of LPA, MIA, or AIS This applies whether a detailed histologic assessment (i.e. proportion of subtypes, etc.) shows a matching or different appearance This applies if one lesion(s) is LPA, MIA or AIS and there are other sub-solid nodules that have not been biopsied This applies whether the nodule(s) are identified preoperatively or only on pathologic examination Foci of AAH are not countedAAH, atypical adenomatous hyperplasia, AIS, adenocarcinoma in situ; GG/L, ground glass/lepidic; LPA, lepidic predominant adenocarcinoma; MIA, minimally invasive adenocarcinomaTable 4: Criteria to Categorize a Tumor as a Pneumonic-Type of AdenocarcinomaClinical CriteriaTumors should be considered pneumonic-type of adenocarcinoma if:The cancer manifests in a regional distribution, similar to a pneumonic infiltrate or consolidation. This applies whether there is one confluent area or multiple regions of disease. The region(s) may be confined to one lobe, in multiple lobes or bilateral, but should involve a regional pattern of distribution (i.e. not focal nodules). The appearance of involved areas may be ground glass, solid consolidation or a combination thereof. This can be applied whether or not the area(s) have been biopsied when there is compelling suspicion of malignancy. This should not be applied to discrete nodules (i.e. GG/L nodules) This should not be applied to central bronchial obstructing tumors with resultant obstructive pneumonia or atelectasisPathologic Correlatesriteria Tumors should be considered pneumonic-type of adenocarcinoma if:There is diffuse distribution of adenocarcinoma throughout a region(s) of the lung, as opposed to a single well demarcated mass or multiple discrete well demarcated nodules. This typically involves an invasive mucinous adenocarcinoma, although a mixed mucinous and non-mucinous pattern may occur. The tumor may show a heterogeneous mixture of of acinar, papillary and micropapillary growth patterns, although it is usually lepidic predominant. GG/L, ground glass/lepidicTable 5: Schematic Summary of Patterns of Disease and TNM Classification of Patients with Lung Cancer with Multiple Pulmonary Sites of Involvement Second PrimaryLung CancerMultifocalGG/L NodulesPneumonic-Typeof AdenocarcinomaSeparateTumor NoduleImagingFeaturesTwo or more distinct masses with imaging characteristic of lung cancer (e.g. spiculated)Multiple ground glass or part-solid nodulesPatchy areas of ground glass and consolidationTypical lung cancer (e.g. solid, spiculated) with separate solid nodule Pathologic FeaturesDifferent histotype or different morphology by comprehensive histologic assessmentAdenocarcinomas with prominent lepidic component (typically varying degrees of AIS, MIA, LPA) Same histology throughout (most often invasive mucinous adenocarcinoma) Distinct masses with the same morphology by comprehensive histologic assessmentTNM ClassificationSeparate cTNM and pTNM for each cancerT based on highest T lesion with (#/m) indicating multiplicity; single N and MT based on size or T3 if in single lobe, T4 or M1a if in different ipsi- or contralateral lobes; single N and MLocation of separate nodule relative to primary site determines if T3, T4 or M1a; single N and MConceptual ViewUnrelated tumorsSeparate tumors, albeit with similaritiesSingle tumor, diffuse pulmonary involvementSingle tumor, with intrapulmonary metastasisAIS, adenocarcinoma in situ; GG/L, ground glass/lepidic; LPA, lepidic predominant adenocarcinoma; MIA, minimally invasive adenocarcinomaFiguresFigure 1: Representative Examples Representative examples of 4 patterns of disease which manifest multiple pulmonary sites of lung cancer. Second primary cancers. A patient with 2 primary lung cancers in the RUL. CT images of each in the left 2 panels, corresponding microscopic images showing an adenocarcinoma and a squamous carcinoma in the next 2 panels. Note that most 2nd primary cancers are of the same (not a different) histologic type.Separate tumor nodules. A patient with a separate tumor nodule of the same histotype as the index tumor. The left panels show CT images of each lesion; the right panels the corresponding microscopic images.Multifocal GG/L lung cancer. A patient with multifocal GG/L tumors in the right upper lobe (who had other GG/L tumors in other lobes). Arrows point to 2 GG/L tumors on CT in the left 2 panels; the next 2 panels show corresponding microscopic images (both were adenocarcinoma with a prominent lepidic component, although with different other adenocarcinoma subtypes). These tumors are classified together as GG/L tumors regardless of such secondary differences.Pneumonic-type of lung cancer. A patient with pneumonic-type of lung cancer (this patient also had focal sites of disease in the RLL). The left panels show CT images of the RUL and RML with the typical regional areas with a ground glass and consolidative appearance; the next panels show the corresponding microscopic images.Adeno, adenocarcinoma; CT, computed tomography; GG/L tumors, tumors with prominent ground glass (imaging) or lepidic (histologic) features; MIA, minimally invasive adenocarcinoma; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; Squam, squamous cell carcinoma.APPENDIX IASLC Staging and Prognostic Factors CommitteePeter Goldstraw, Past Chair, Royal Brompton Hospital and Imperial College, London, United Kingdom; Ramón Rami-Porta, Chair, Hospital Universitari Mutua Terrassa, Terrassa, Spain; Hisao Asamura, Chair Elect, Keio University, Tokyo, Japan; David Ball, Peter MacCallum Cancer Centre, Melbourne, Australia; David G. Beer, University of Michigan, Ann Arbor, MI, United States of America (USA); Ricardo Beyruti, University of Sao Paulo, Brazil; Vanessa Bolejack, Cancer Research And Biostatistics, Seattle, WA, USA; Kari Chansky, Cancer Research And Biostatistics, Seattle, WA, USA; John Crowley, Cancer Research And Biostatistics, Seattle, WA, USA; Frank Detterbeck, Yale University, New Haven, CT, USA; Wilfried Ernst Erich Eberhardt, West German Cancer Centre, University Hospital, Ruhrlandklinik, University Duisburg-Essen, Essen, Germany; John Edwards, Northern General Hospital, Sheffield, United Kingdom; Fran?oise Galateau-Sallé, Centre Hospitalier Universitaire, Caen, France; Dorothy Giroux, Cancer Research And Biostatistics, Seattle, WA, USA; Fergus Gleeson, Churchill Hospital, Oxford, United Kingdom; Patti Groome, Queen’s Cancer Research Institute, Kingston, Ontario, Canada; James Huang, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Catherine Kennedy, University of Sydney, Sydney, Australia; Jhingook Kim, Samsung Medical Center, Seoul, Korea; Young Tae Kim, Seoul National University, Seoul, South Korea; Laura Kingsbury, Cancer Research And Biostatistics, Seattle, WA, USA; Haruhiko Kondo, Kyorin University Hospital, Tokyo, Japan; Mark Krasnik, Gentofte Hospital, Copenhagen, Denmark; Kaoru Kubota, Nippon Medical School Hospital, Tokyo, Japan; Antoon Lerut, University Hospitals, Leuven, Belgium; Gustavo Lyons, British Hospital, Buenos Aires, Argentina; Mirella Marino, Regina Elena National Cancer Institute, Rome, Italy; Edith M. Marom, MD Anderson Cancer Center, Houston, TX, USA; Jan van Meerbeeck, Antwerp University Hospital, Edegem (Antwerp), Belgium; Alan Mitchell, Cancer Research And Biostatistics, Seattle, WA, USA; Takashi Nakano, Hyogo College of Medicine, Hyogo, Japan; Andrew G. Nicholson, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, United Kingdom; Anna Nowak, University of Western Australia, Perth, Australia; Michael Peake, Glenfield Hospital, Leicester, United Kingdom; Thomas Rice, Cleveland Clinic, Cleveland, OH, USA; Kenneth Rosenzweig, Mount Sinai Hospital, New York, NY, USA; Enrico Ruffini, University of Torino, Torino, Italy; Valerie Rusch, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nagahiro Saijo, National Cancer Center Hospital East, Chiba, Japan; Paul Van Schil, Antwerp University Hospital, Edegem (Antwerp), Belgium; Jean-Paul Sculier, Institut Jules Bordet, Brussels, Belgium; Lynn Shemanski, Cancer Research And Biostatistics, Seattle, WA, USA; Kelly Stratton, Cancer Research And Biostatistics, Seattle, WA, USA; Kenji Suzuki, Juntendo University, Tokyo, Japan; Yuji Tachimori, National Cancer Center, Tokyo, Japan; Charles F. Thomas Jr, Mayo Clinic, Rochester, MN, USA; William Travis, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Ming S. Tsao, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Andrew Turrisi, Sinai Grace Hospital, Detroit, MI, USA; Johan Vansteenkiste, University Hospitals, Leuven, Belgium; Hirokazu Watanabe, National Cancer Center Hospital, Tokyo, Japan; Yi-Long Wu, Guangdong Provincial Peoples Hospital, Guangzhou, People’s Republic of China. Advisory Board of the IASLC Mesothelioma DomainPaul Baas, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Jeremy Erasmus, MD Anderson Cancer Center, Houston, TX, USA; Seiki Hasegawa, Hyogo College of Medicine, Hyogo, Japan; Kouki Inai, Hiroshima University Postgraduate School, Hiroshima, Japan; Kemp Kernstine, City of Hope, Duarte, CA, USA; Hedy Kindler, The University of Chicago Medical Center, Chicago, IL, USA; Lee Krug, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Kristiaan Nackaerts, University Hospitals, Leuven, Belgium; Harvey Pass, New York University, NY, USA; David Rice, MD Anderson Cancer Center, Houston, TX, USA. Advisory Board of the IASLC Thymic Malignancies DomainConrad Falkson, Queen’s University, Ontario, Canada; Pier Luigi Filosso, University of Torino, Italy; Giuseppe Giaccone, Georgetown University, Washington, DC, USA; Kazuya Kondo, University of Tokushima, Tokushima, Japan; Marco Lucchi, University of Pisa, Pisa, Italy; Meinoshin Okumura, Osaka University, Osaka, Japan.Advisory Board of the IASLC Esophageal Cancer DomainEugene Blackstone, Cleveland Clinic, OH, USA. Participating Institutions in the new IASLC Lung Cancer Staging ProjectF. Abad Cavaco and E. Ansótegui Barrera, Hospital La Fe, Valencia, Spain; J. Abal Arca and I. Parente Lamelas, Complejo Hospitalario de Ourense, Ourense, Spain; A. Arnau Obrer and R. Guijarro Jorge, Hospital General Universitario de Valencia, Valencia, Spain; D. Ball, Peter MacCallum Cancer Centre, Melbourne, Australia; G. K. Bascom, Good Samaritan Hospital, Kearney, NE, USA; A. I. Blanco Orozco and M. A. González Castro, Hospital Virgen del Rocío, Sevilla, Spain; M. G. Blum, Penrose Cancer Center, Colorado Springs, USA; D. Chimondeguy, Hospital Universitario Austral, Argentina; V. Cvijanovic, Military Medical Academy, Belgrade, Serbia; S. Defranchi, Hospital Universitario-Fundacion Favaloro, Buenos Aires, Argentina; B. de Olaiz Navarro, Hospital de Getafe, Getafe, Spain; I. Escobar Campuzano and I. Macía Vidueira, Hospital de Bellvitge, L’Hospitalet de Llobregat, Spain; E. Fernández Araujo and F. Andreo García, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; K. M. Fong, Prince Charles Hospital, Brisbane, Australia; G. Francisco Corral and S. Cerezo González, Hospital La Mancha Centro, Ciudad Real, Spain; J. Freixinet Gilart, Hospital Universitario ‘Dr. Negrín’, Las Palmas de Gran Canaria, Spain; L. García Arangüena, Hospital Sierrallana, Torrelavega, Spain; S. García Barajas, Hospital Infanta Cristina, Badajoz, Spain; P. Girard, L'Institut Mutualiste Montsouris, Paris, France; T. Goksel, Turkish Thoracic Society, Turkey; M. T. González Budi?o, Hospital General Universitario de Oviedo, Oviedo, Spain; G. González Casaurrán, Hospital Gregorio Mara?ón, Madrid, Spain; J. A. Gullón Blanco, Hospital San Agustín, Avilés, Spain; J. Hernández Hernández, Hospital de ?vila, Avila, Spain; H. Hernández Rodríguez, Hospital Universitario de Tenerife, Santa Cruz de Tenerife, Spain; J. Herrero Collantes, Hospital Universitario Nuestra Se?ora de la Candelaria, Santa Cruz de Tenerife, Spain; M. Iglesias Heras, Hospital de ?vila, ?vila, Spain; J. M. Izquierdo Elena, Hospital Nuestra Se?ora de Aránzazu, Donostia, Spain; E. Jakobsen, Danish Lung Cancer Registry, Denmark; S. Kostas, Athens School of Medicine, Athens, Greece; P. León Atance and A. Nú?ez Ares, Complejo Hospitalario de Albacete, Albacete, Spain; M. Liao, Shanghai Lung Tumor Clinical Medical Center, Shanghai, China; M. Losanovscky, Clinica y Maternidad Suizo Argentina, Buenos Aires, Argentina; G. Lyons, Hospital Britanico de Buenos Aires, Buenos Aires, Argentina; R. Magaroles and L. De Esteban Júlvez, Hospital Joan XXIII, Tarragona. Spain; M. Mari?án Gorospe, Hospital de San Pedro de Logro?o, Logro?o, Spain; B. McCaughan and C. Kennedy, University of Sydney, Sydney, Australia; R. Melchor ??iguez, Fundación Jiménez Díaz, Madrid, Spain; L. Miravet Sorribes, Hospital La Plana, Castellón, Spain; S. Naranjo Gozalo and C. ?lvarez de Arriba, Hospital Universitario Marqués de Valdecilla, Santander, Spain; M. Nú?ez Delgado, Hospital de Meixoeiro, Vigo, Spain; J. Padilla Alarcón and J. C. Pe?alver Cuesta, Instituto Valenciano de Oncología, Valencia, Spain; J. S. Park, Samsung Medical Center, Seoul, South Korea; H. Pass, New York University Langone Medical Center and Cancer Center, New York, USA; M. J. Pavón Fernández, Hospital ‘Severo Ochoa’, Leganés, Spain; M. Rosenberg, Alexander Fleming Institute and Hospital de Rehabilitación Respiratoria, Buenos Aires, Argentina; E. Ruffini, University of Torino, Torino , Italy; V. Rusch, Memorial Sloan-Kettering Cancer Center, New York, USA; J. Sánchez de Cos Escuín, Hospital de Cáceres, Cáceres, Spain; A. Saura Vinuesa, Hospital de Sagunto, Sagunto, Spain; M. Serra Mitjans, Hospital Universitari Mutua Terrassa, Terrassa, Spain; T.E. Strand, Cancer Registry of Norway, Norway; D. Subotic, Clinical Centre of Serbia, Belgrade, Serbia; S. Swisher, M.D. Anderson Cancer Center (MDACC), Houston, USA; R. Terra, University of Sao Paulo Medical Center, Sao Paulo, Brazil; C. Thomas, Mayo Clinic Rochester, Rochester, MN, USA; K. Tournoy, University Hospital Ghent, Belgium; P. Van Schil, Antwerp University Hospital, Edegem (Antwerp), Belgium; M. Velasquez, Fundacion Clinica Valle del Lili, Cali, Colombia; Y. L. Wu, Guangdong General Hospital, Guangzhou, China; K. Yokoi, Japanese Joint Committee for Lung Cancer Registry, Osaka, Japan. Multiple Pulmonary Sites of Cancer WorkgroupJeremy Erasmus, MD Anderson Cancer Center, Houston, TX, USA; Douglas Flieder, Fox Chase Cancer Center, Philadelphia, PA, USA; Myrna Godoy, MD Anderson Cancer Center, Houston, TX, USA; Jin Mo Goo, Seoul National University College of Medicine, Seoul, South Korea; Lawrence R. Goodman, Medical College of Wisconsin, Milwaukee, WI, USA; Jim Jett, National Jewish Health System, Denver, CO, USA; Paul de Leyn, Catholic University, Leuven, Belgium; Alberto Marchevsky, Cedars Sinai Health System, Los Angeles, CA, USA; Heber MacMahon, University of Chicago, Chicago, IL, USA: David Naidich, New York University, New York, NY, USA; Morohito Okada, Hiroshima University, Hiroshima, Japan; Marina Perlman, Tel-Aviv University, Ramat Gan, Israel; Charles Powell, Mount Sinai School of Medicine, New York, NY, USA; Paul van Schil, Antwerp University Hospital, Edegem (Antwerp), Belgium; Ming S. Tsao, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Arne Warth, University of Heidelberg, Germany.References: ADDIN EN.REFLIST 1 Fonseca A, Detterbeck FC. How many names for a rose: Inconsistent classification of multiple foci of lung cancer due to ambiguous rules. Lung Cancer 2014; 85:7-112 Homer R. Pathologists' staging of multiple foci of lung cancer. Am J Clin Pathol 2015; 143:701-7063 Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244-2854 WHO. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th Edition ed. Lyon, France: International Agency for Research on Cancer (IARC), 2015; 5 Detterbeck F, Arenberg D, Asamura H, et al. The IASLC Lung Cancer Staging Project: Proposals for revisions of the classfication of additional tumor nodules in patients with lung cancer in the forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; in press6 Detterbeck F, Arenberg D, Asamura H, et al. The IASLC Lung Cancer Staging Project: Criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors. J Thorac Oncol 2015; in process7 Detterbeck F, Arenberg D, Asamura H, et al. The IASLC Lung Cancer Staging Project: Multifocal lung cancer presenting as multiple nodules with ground glass features. J Thorac Oncol 2015; in process8 Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706-7149 Goldstraw Pea. The IASLC Lung Cancer Staging Project: proposals for the revision of the stage grouping in the forthcoming (8th) edition of the TNM classification of lung cancer. J Thorac Oncol 2015; in preparation10 Wislez M, Massiani M-A, Milleron B, et al. Clinical Characteristics of Pneumonic-Type Adenocarcinoma of the Lung. Chest 2003; 123:1868-187711 Akira M, Atagi S, Kawahara M, et al. High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. Am J Roentgenol 1999; 173:1623-162912 Battafarano RJ, Meyers BF, Guthrie TJ, et al. Surgical resection of multifocal non-Small cell lung cancer is associated with prolonged survival. Ann Thorac Surg 2002; 74:988-99413 Nanki N, Fujita J, Hojo S, et al. Evaluation of the clonality of multilobar bronchioloalveolar carcinoma of the lung. Am J Clin Oncol 2002; 25:291-29514 Barlesi F, Doddoli C, Gimenez C, et al. Bronchioloalveolar carcinoma: myths and realities in the surgical management. Eur J Cardiothorac Surg 2003; 24:159-16415 de Perrot M, Chernenko S, Waddell TK, et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease. J Clin Oncol 2004; 22:4351-435616 Ahmad U, Wang Z, Bryant AS, et al. Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry. Ann Thorac Surg 2012; 94:935-94117 Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society. Radiology 2013; 266:304-31718 Travis D, Asamura H, Bankier AA, et al. The IASLC Lung Cancer Staging Project: Proposals for coding T categories for adenocarcinoma in situ and minimally invasive adenocarcinoma, and for measurement of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2015; in process19 Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM Classification for Lung Cancer J Thorac Oncol 2015; 10:990-100320 Valastyan S, Weinberg Robert??A. Tumor Metastasis: Molecular Insights and Evolving Paradigms. Cell 2011; 147:275-29221 Weinberg RA. Mechanisms of malignant progression. Carcinogenesis 2008; 29:1092-109522 Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med 2013; 19:1450-1464 ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.